Express Healthcare
Home  »  News  »  Siemens Healthineers inaugurates manufacturing facility for molecular diagnostic kits in Gujarat

Siemens Healthineers inaugurates manufacturing facility for molecular diagnostic kits in Gujarat

0 148
Read Article

Production capacity of 25 million tests per annum, that can be ramped up further if required

COVID-19 pandemic has led to heightened awareness and needs for Molecular testing infrastructure in the Country. Siemens Healthineers has announced local manufacturing of molecular testing kits, including COVID-19 testing (IMDX SARS-CoV2 Multiplex RTPCR) as well as other Molecular testing kits in its state-of-art facility at Vadodara, Gujarat.

The facility was inaugurated on August 27, 2021, jointly by Krishnan Seshan, Executive Director, Finance and Administration, Siemens Healthcare Private Limited, and Arpan Malhotra, Head of Diagnostics, Siemens Healthineers, India.

Arpan Malhotra on this occasion said, “This investment reaffirms our belief in India the growth story and our commitment to the Indian healthcare sector. As a pioneer in diagnostics manufacturing in India, local production of molecular testing kits is a breakthrough in scaling up testing, especially during a crisis. These kits are designed and developed by Siemens Healthineers along with eminent researchers from Indian universities and research centers, reinforcing our open policy to work and to enhance our efforts in expanding precision medicine.”

IMDX family of molecular diagnostics assays tracks infectious diseases, human genetics and oncology marker based on molecular RT-PCR technology to address equitable access to the diagnostics value chain, starting with advanced genomics driven IMDX SARS-CoV2 Multiplex RT-PCR kit.

The IMDX SARS-CoV2 Multiplex RTPCR kits will be produced in compliance with the guidelines prescribed by the Indian statutory bodies and confirm to the highest global standards.

Being pioneers in diagnostic manufacturing, Siemens Healthineers has maintained a high level of quality and reliability in diagnostics operations for over 40 years in India and has been consistently tracking changes in consumer demands and met most consumer requirements at the right time. The existing manufacturing facility licensed as per Medical Device Rules, 2017 (MDR 2017), comprises of two product lines namely urine analysis strips and AUTOPAK Biochemistry Reagents. As a part of the skill development initiative, the facility also serves as a centre of excellence for training in laboratory diagnostics, point-of-care testing and diagnostic imaging, across the South Asia region.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More